President Biden on Oct. 26, 2022 (Oliver Contreras/Sipa USA/Sipa via AP Images)

Al­ny­lam blames the In­fla­tion Re­duc­tion Act for a PhI­II cut — would it have sold enough for ne­go­ti­a­tions?

Al­ny­lam Phar­ma­ceu­ti­cals, the phar­ma mar­ket’s leader in RNAi ther­a­pies, re­port­ed its third quar­ter earn­ings Thurs­day, up­dat­ing share­hold­ers on its pipeline progress and ini­tial sales fig­ures for the re­cent­ly ap­proved vutrisir­an (mar­ket­ed as Amvut­tra).

But tucked away near the bot­tom of its re­port, the com­pa­ny re­vealed it would scrap plans to launch a Phase III tri­al for vutrisir­an in the rare Star­gardt dis­ease, ap­pear­ing to blame Pres­i­dent Joe Biden’s In­fla­tion Re­duc­tion Act in the process.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.